A Multicenter Phase 2 Trial of Camrelizumab Plus Famitinib for Women with Recurrent or Metastatic Cervical Squamous Cell Carcinoma.
Nature communications（2022）
关键词
Cervical cancer,Drug development,Science,Humanities and Social Sciences,multidisciplinary
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要